TY - JOUR
T1 - Expression of urocortin III/stresscopin in human heart and kidney
AU - Takahashi, Kazuhiro
AU - Totsune, Kazuhito
AU - Murakami, Osamu
AU - Saruta, Masayuki
AU - Nakabayashi, Masao
AU - Suzuki, Takashi
AU - Sasano, Hironobu
AU - Shibahara, Shigeki
PY - 2004/4
Y1 - 2004/4
N2 - Urocortin III (Ucn III)/stresscopin (SCP) is a novel peptide of the corticotropin-releasing factor (CRF) family and is a specific ligand for the CRF type 2 receptor. We wished to clarify whether Ucn III/SCP is expressed in the human heart and kidney. Immunoreactive Ucn III was detected by RIA in the human heart (0.74-1.15 pmol/g wet weight, mean ± SEM; n = 4) and kidney (1.21 ± 0.30 pmol/g wet weight), which were obtained at autopsy. These levels were comparable to the levels in pituitary (2.72 ± 0.13 pmol/g wet weight; n = 3) and brain tissues (∼1-2 pmol/g wet weight). Furthermore, immunoreactive Ucn III was present in human plasma (51.8 ± 16.0 pmol/ liter, n = 5) and urine (266 ± 20 pmol/liter; n = 5) obtained from healthy subjects. Reverse-phase HPLC showed a broad peak of immunoreactive Ucn III eluting in the position of synthetic Ucn III in the heart, kidney, and hypothalamus. Material eluting in the position of SCP was also found in the HPLC analysis of these tissue extracts. Immunocytochemistry showed positive staining of Ucn III in the myocardium and the renal tubules, particularly distal tubules. RT-PCR showed expression of Ucn III mRNA in the brain, pituitary, heart, and kidney. The present study has shown expression of Ucn III/SCP in the human heart and kidney as well as brain and pituitary tissues and its presence in plasma and urine. Ucn III/SCP may therefore regulate the cardiac and renal function as a local factor and a circulating hormone.
AB - Urocortin III (Ucn III)/stresscopin (SCP) is a novel peptide of the corticotropin-releasing factor (CRF) family and is a specific ligand for the CRF type 2 receptor. We wished to clarify whether Ucn III/SCP is expressed in the human heart and kidney. Immunoreactive Ucn III was detected by RIA in the human heart (0.74-1.15 pmol/g wet weight, mean ± SEM; n = 4) and kidney (1.21 ± 0.30 pmol/g wet weight), which were obtained at autopsy. These levels were comparable to the levels in pituitary (2.72 ± 0.13 pmol/g wet weight; n = 3) and brain tissues (∼1-2 pmol/g wet weight). Furthermore, immunoreactive Ucn III was present in human plasma (51.8 ± 16.0 pmol/ liter, n = 5) and urine (266 ± 20 pmol/liter; n = 5) obtained from healthy subjects. Reverse-phase HPLC showed a broad peak of immunoreactive Ucn III eluting in the position of synthetic Ucn III in the heart, kidney, and hypothalamus. Material eluting in the position of SCP was also found in the HPLC analysis of these tissue extracts. Immunocytochemistry showed positive staining of Ucn III in the myocardium and the renal tubules, particularly distal tubules. RT-PCR showed expression of Ucn III mRNA in the brain, pituitary, heart, and kidney. The present study has shown expression of Ucn III/SCP in the human heart and kidney as well as brain and pituitary tissues and its presence in plasma and urine. Ucn III/SCP may therefore regulate the cardiac and renal function as a local factor and a circulating hormone.
UR - http://www.scopus.com/inward/record.url?scp=1942472634&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1942472634&partnerID=8YFLogxK
U2 - 10.1210/jc.2003-031663
DO - 10.1210/jc.2003-031663
M3 - Article
C2 - 15070962
AN - SCOPUS:1942472634
SN - 0021-972X
VL - 89
SP - 1897
EP - 1903
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 4
ER -